Sensible Biotechnologies
YC S21Oxford, GB · Founded 2021 · 24 employees · 3 known investors
Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.
AI & Machine LearningBiotechDeep TechHealthtechSynthetic BiologyManufacturingTherapeuticsBiotechnologyin /sensible-biotechnologies/@sensible_bio
Founders & leadership· Y Combinator alumni (S21)
Miroslav Gasparekin𝕏Founder
Marian KupculakinFounder
Investors · 3
In the news
- Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible’s Unique Cell-Based mRNA Design and Manufacturing Platformfinance.yahoo.com · 2025
- Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More Than 90% with AI Platform Built on NVIDIA Technologybusinesswire.com · 2025
- Sensible Biotechnologies - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2023
- Sensible Biotechnologies - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2023
- Sensible Biotechnologies Raises $4.2mn in a Pre-Seed Financing Round to Revolutionize mRNA Manufacturing - BioSpacebiospace.com · 2023
- Sensible Biotechnologies Raises $4.2M in Pre-Seed Financingfinsmes.com · 2023
- Sensible Biotechnologies Partners with Ginkgo to Develop Novel mRNA Manufacturing Platformgenengnews.com · 2023
- Sensible Biotechnologies Announces Partnership with Ginkgo Bioworks to Develop Novel mRNA Manufacturing Platformprnewswire.com · 2023